NeXeption, LLC is a biopharmaceutical management company that brings together product opportunities, management expertise and the necessary funding to reach compelling partnership milestones. The NeXeption management team has a proven track record in raising capital, operating development stage companies and forming strategic partnerships to advance products for the benefit of patients.


JANUARY 2, 2014
NeXeption, LLC Forms New Company Alexar Therapeutics, Inc. to Develop Novel LXR Agonist Portfolio for Dermatologic Indications; Raises $21.5 Million in Series A Financing

Dave Pfeiffer Named Alexar Chief Executive Officer

NOVEMBER 6, 2013
Aclaris Therapeutics Initiates IND-Directed Program for A-101 for the Treatment of Seborrheic Keratosis, Common Type of Skin Tumor

SEPTEMBER 19, 2013
Actelion closes acquisition of privately-held Ceptaris Therapeutics adding Valchlor to Actelion’s product portfolio